Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb

Nuclear Medicine and Biology

Volumn 27, Issue 1, 2000, Pages 93-100

  Chappell, Lara L ^a   Dadachova, Ekaterina ^a   Milenic, Diane E ^b   Garmestani, Kayhan ^a   Wu, Chuanchu ^c   Brechbiel, Martin W ^a  

^a Radioimmune and Inorg Chem Section   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c REL TEK   (United States)

Author keywords

Lead 203; Macrocycles; Radioimmunoconjugate; Radioimmunoimaging; Radioimmunotherapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; CHELATING AGENT; LEAD 203; LEAD 212; MONOCLONAL ANTIBODY; RADIOISOTOPE;

ARTICLE; CHELATION; CONJUGATE; CONTROLLED STUDY; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; PH; RADIOIMMUNOTHERAPY; SERUM;

CHELATING AGENTS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HETEROCYCLIC COMPOUNDS; HUMANS; HYDROGEN-ION CONCENTRATION; ISOTHIOCYANATES; LEAD RADIOISOTOPES; MOLECULAR STRUCTURE;

EID: 0033954403     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(99)00086-4     Document Type: Article

References (39)

1. 177Lu-CC49 A phase I/II study . Gynecol. Oncol. 65:1997;94-101.
2. 2 . Angew. Chem. Int. Ed. Engl. 33:1994;773-775.
3. 3+. Inorg. Chem. 35, 7466-7467.
4. Carlton L., Hancock R. D., Maumela H. and Wainwright K. P. (1994) Stability enhancement of heavy-metal-macrocycle complexes via pendant amide coordination. J. Chem. Soc., Chem. Commun. 1007-1008.
5. Chatal J.F., Faivre-Chauvet A., Bardies M., Peltier P., Gautherot E., Barber J. Bifunctional antibodies for radioimmunotherapy. Hybridoma. 14:1995;125-128.
6. Colcher D., Esteban J.E., Carrasquillo J.A., Sugarbaker P., Reynolds J.C., Bryant G., Larson S.M., Schlom J. Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Cancer Res. 47:1987;4218-4224.
7. Colcher D., Minelli F.M., Roselli M., Muraro R., Simpson-Milenic D., Schlom J. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. Cancer Res. 48:1988;4597-4603.
8. Cox J. P. L., Jankowski K. J., Kataky R., Parker D., Beeley N. R. A., Boyce B. A., Eaton M. A. W., Millar K., Millican A. T., Harrison A. and Walker C. (1989) Synthesis of a kinetically stable Y-90 labeled macrocycle antibody conjugate. J. Chem. Soc., Chem. Commun. 797-798.
9. Dadachova E., Chappell L. and Brechbiel M. W. (in press) Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates. Nucl. Med. Biol.
10. Fraker P.J., Speck J.C. Protein and cell membrane iodinations with a sparingly soluble chloramide 1,3,4,6-terachloro-3α,6α-diphenylglycouril. Biochem. Biophys. Res. Commun. 80:1978;849-857.
11. Gansow O.A. Newer approaches to the radiolabeling of monoclonal antibodies by the use of metal chelates. Nucl. Med. Biol. 18:1991;369-381.
12. Hammond P.B. The effects of chelating agents on the tissue distribution and excretion of lead. Toxicol. Appl. Pharmacol. 18:1971;296-310.
13. 212Bi-DOTMP An alpha particle emitting bone-seeking agent for targeted radiotherapy . Nucl. Med. Biol. 24:1997;231-237.
14. 203Pb using a lead-selective extraction chromatographic resin. Appl. Radiat. Isot. 49:1998;357-359.
15. Horak E., Hartmann F., Garmestani K., Wu C.-C., Brechbiel M.W., Gansow O.A., Landolfi N.F., Waldmann T.A. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. J. Nucl. Med. 38:1997;1944-1958.
16. Huneke R.B., Pippin C.G., Squire R.A., Brechbiel M.W., Gansow O.A., Strand M. Effective α-particle-mediated radioimmunotherapy of murine leukemia. Cancer Res. 52:1992;5818-5820.
17. Kumar K., Magerstädt M. and Gansow O. A. (1989) Lead(II) and bismuth(III) complexes of the polyazacycloalkane-N-acetic acids nota, dota, and teta. J. Chem. Soc., Chem. Commun. 145-146.
18. Laemmli U.K. Cleavage of structural proteins during assembly of the head of the bacteriophage T4. Nature (London). 227:1970;680-685.
19. Lewis M.R., Shively J.E. Maleimidocysteineamido-DOTA derivatives New reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions . Bioconjug. Chem. 9:1998;72-86.
20. Lui Y., Wu C. Radiolabeling of monoclonal antibodies with metal chelates. Pure Appl. Chem. 63:1991;427-463.
21. Lowry O.H., Rosebrough N.J., Farr A., Randall A.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
22. McDevitt M.R., Sgouros G., Finn R.D., Humm J.L., Jurcic J.G., Larson S.M., Scheinberg D.A. Radioimmunotherapy with alpha-emitting nuclides. Eur. J. Nucl. Med. 25:1998;1341-1351.
23. McMurry T.J., Brechbiel M.W., Kumar K., Gansow O.A. Convenient synthesis of bifunctional tetraaza macrocycles. Bioconjug. Chem. 3:1992;108-117.
24. Maumela H., Hancock R.D., Carlton L., Reibenspies J.H., Wainwright K.P. The amide oxygen as a donor group. Metal ion complexing properties of tetra-N-acetamide substituted cyclen A crystallographic, NMR, molecular mechanics, and thermodynamic study . J. Am. Chem. Soc. 117:1995;6698-6707.
25. Milenic D.E., Roselli M., Brechbiel M.W., Pippin C.G., McMurry T.J., Carrasquillo J.A., Colcher D., Lambrecht R., Gansow O.A., Schlom J. In vivo evaluation of a lead-labelled monoclonal antibody using the DOTA ligand. Eur. J. Nucl. Med. 225:1998;471-480.
26. 2-. Radiochim. Acta. 16:1993;1-10.
27. Moi M.K., Meares C.F., DeNardo S.J. The peptide way to macrocyclic bifunctional chelating-agents-synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴- tetraacetic acid and study of its yttrium(III) complex. J. Am. Chem. Soc. 110:1988;6266-6267.
28. Muraro R., Kuroki M., Wunderlich D., Poole D.J., Colcher D., Thor A., Greiner J.W., Simpson J.F., Molinolo A., Noguchi P., Schlom J. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. Cancer Res. 48:1988;4588-4596.
29. Parker D. Tumour targeting with radiolabelled macrocycle - antibody conjugates. Chem. Soc. Rev. 19:1990;271-291.
30. Peterson J.J., Pak R.H., Meares C.F. Total solid-phase synthesis of 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid-functionalized peptides for radioimmunotherapy. Bioconjug. Chem. 10:1999;316-320.
31. 203Pb labeled monoclonal antibodies . Inorg. Chim. Acta. 239:1995;43-51.
32. 212Pb-labeled monoclonal antibody in the treatment of murine erythroleukemia. Int. J. Rad. Oncol. Biol. Phys. 34:1996;609-616.
33. Ruegg C.L., Anderson-Berg W.T., Brechbiel M.W., Mirzadeh S., Gansow O.A., Strand M. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res. 50:1990;4221-4226.
34. Sharifi J., Khawli L.A., Hornick J.L., Epstein A.L. Improving monoclonal antibody pharmacokinetics via chemical modification. Quart. J. Nucl. Med. 42:1998;242-249.
35. Srivastava S.C., Mausner L.F., Mease R.C., Meinken G.E., Joshi V., Kolsky K., Sweet M., Steplewski Z. Development and evaluation of copper-67 and samarium-153 labeled conjugates for tumor radioimmunotherapy. Int. J. Pharmacog. 33:1995;92-101.
36. Srivastava S.C. Criteria for the selection of radionuclides for targeting nuclear antigens for cancer radioimmunotherapy. Cancer Biother. Radiopharm. 11:1996;43-50.
37. Stimmel J.B., Kull F.C. Samarium-153 and lutetium-177 chelation properties of selected macrocyclic and acyclic ligands. Nucl. Med. Biol. 25:1998;117-125.
38. III complexes. J. Org. Chem. 58:1993;1955-1958.
39. 212Pb chelates. Radioact. Radiochem. 3:1994;18-21.